Quantcast

Latest Tarceva Stories

2008-10-06 09:00:09

Genentech and OSI Pharmaceuticals have announced that a randomized Phase III study evaluating Avastin in combination with Tarceva in patients with advanced non-small cell lung cancer whose disease had progressed following platinum-based chemotherapy did not meet its primary endpoint of improving overall survival compared to Tarceva in combination with placebo. However, there was clear evidence of clinical activity with improvements in the secondary endpoints of progression-free survival and...

2008-10-06 03:00:07

Genentech, Inc. (NYSE:DNA) and OSI Pharmaceuticals, Inc. (Nasdaq:OSIP) today announced that a randomized Phase III study (BeTa Lung) evaluating Avastin(R) (bevacizumab) in combination with Tarceva(R) (erlotinib) in patients with advanced non-small cell lung cancer (NSCLC) whose disease had progressed following platinum-based chemotherapy did not meet its primary endpoint of improving overall survival compared to Tarceva in combination with placebo. However, there was clear evidence of...

2008-09-08 09:00:52

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) announced today the appointment of Nicholas Bacopoulos, Ph.D., to its Board of Directors. Dr. Bacopoulos has more than 25 years of experience at leading biotechnology and pharmaceutical companies, serving in multiple executive positions and managing the discovery and development of novel anticancer agents. "Nicholas Bacopoulos is a valuable addition to Cyclacel's board of directors bringing extensive knowledge and understanding of...

2008-07-15 09:00:16

OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today that it has initiated a Phase I clinical trial of OSI-027, an oral, potent and selective inhibitor of both the TORC1 and TORC2 complexes that inhibits the kinase activity associated with mTOR (mammalian target of rapamycin). The study is designed to determine the maximum tolerated dose (MTD) and to establish the recommended dose and dosing schedule for Phase II trials, and will evaluate the safety and pharmacokinetic profiles of...

2008-07-14 09:00:14

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP) announced the publication of a study conducted by Cyclacel scientists showing synergistic activity between its investigational therapy seliciclib and multiple epidermal growth factor receptor (EGFR) inhibitors, including erlotinib (Tarceva(R)) in models of non-small cell lung cancer and the HER2 targeting agent, trastuzumab (Herceptin(R)) in models of breast cancer. These preclinical results were published in the July issue of the...

2008-07-07 09:00:16

* Alocrest(tm) Phase 1 Data Demonstrates Potential for Improved Safety and Efficacy Compared to Conventional Vinorelbine * Menadione Topical Lotion Restores Kinase Activity and Does Not Inhibit the Anti-Tumor Effect of Erlotinib (Tarceva(r)) in Preclinical Models SOUTH SAN FRANCISCO, Calif., July 7, 2008 (PRIME NEWSWIRE) -- Hana Biosciences (Nasdaq:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, presented data for two of the...

2006-06-05 13:15:42

LOS ANGELES (Reuters) - A mid-stage trial suggests that a combination of cancer drugs Avastin and Tarceva can prolong survival in patients with advanced lung cancer, compared with chemotherapy alone, drug makers Genentech Inc. and OSI Pharmaceuticals said on Monday Avastin, made by Genentech, is the first cancer drug designed to work by cutting off blood supply to tumors. Tarceva, a product of Genentech and OSI, is an oral drug designed to target the human epidermal growth factor...

2006-06-03 13:00:00

By Ransdell Pierson NEW YORK -- A Pfizer Inc. kidney cancer drug has also shown promise in a small mid-stage trial as a treatment for the most common form of lung cancer, researchers said on Saturday. The new study involved 63 patients whose non-small cell lung cancer had progressed despite earlier treatments with standard chemotherapy. All patients were then given Pfizer's once-daily pill, Sutent, as a stand-alone treatment and continued to take it until their disease progressed. Tumors...

2006-06-01 15:29:13

WASHINGTON (Reuters) - Adding a prescription arthritis drug to a targeted cancer therapy triples the number of lung cancer patients who are helped, U.S. researchers said on Thursday. Pfizer's anti-inflammatory drug Celebrex, given along with OSI Pharmaceuticals Inc.'s Tarceva, increased response rates in lung cancer patients from about 10 percent to 33 percent, reported the researchers at the University of California, Los Angeles. The study, published in the journal Clinical Cancer...

2005-10-19 07:19:29

CHICAGO (Reuters) - Genentech Inc. said on Tuesday early results from a mid-stage trial show that combining lung cancer drug Tarceva with Avastin works no better than Avastin alone in patients with advanced kidney cancer, sending shares of Tarceva partner OSI Pharmaceuticals Inc. down 7 percent. As a result, the world's No. 2 biotechnology company said it will not pursue further studies of the Avastin/Tarceva combination in kidney cancer but will continue to analyze the results of...


Word of the Day
lunula
  • A small crescent-shaped structure or marking, especially the white area at the base of a fingernail that resembles a half-moon.
This word is a diminutive of the Latin 'luna,' moon.
Related